CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
October 2017—Quidel announced a revised definitive agreement with Alere for its pending acquisition of Alere’s B-type Natriuretic Peptide assay business run on Beckman Coulter analyzers under which post-acquisition, Quidel will undertake direct commercial responsibility for all BNP sales worldwide. The pending acquisition of Alere’s Triage MeterPro cardiovascular and toxicology assets remains substantially unchanged. These businesses are being divested by Alere pending antitrust approvals required for Abbott’s pending acquisition of Alere. The acquisitions by Quidel are subject to the completion of Abbott’s acquisition of Alere, as well as regulatory approvals and other customary closing conditions.
Quidel will acquire the Triage and BNP businesses for a total consideration of up to $680 million, comprising the previously announced $400 million for the Triage business, $40 million in contingent consideration, and $240 million in deferred consideration for the BNP business. The deal was expected to close by Sept. 30.
Quidel, 858-453-4338